Fishawack provides fully-integrated, cross-border services to global pharmaceutical organisations. It provides a variety of medical communications, market access and pharmacovigilance services to clients to drive the commercialisation of drug compounds. Its services are typically provided from phase II/III clinical trial stage through to post-approval and last for the full lifecycle of the patents on compounds.
In January 2017 LDC backed the management buyout of Fishawack in a deal that values the business at £38million. LDC has committed further equity to accelerate Fishawack’s growth strategy, including potential acquisitions.
The investment is a tertiary buyout and will enable the Management team to accelerate its buy and build strategy through a number of targeted acquisitions over the medium term, in addition to supporting the growth of current client relationships.
Since LDC’s investment, Fishawack has made five acquisitions as part of its international buy-and-build strategy. The firm has grown its global headcount to more than 750, placing it among the largest independent healthcare agencies globally. Its most recent acquisition was of US-based healthcare communications agency, 2e Creative, in August 2019.
We are an ambitious team and want to build on this further, continuing to strengthen our market-leading proposition and further building our presence internationally. In LDC we have a partner that is not only able to provide the financial backing we need to do this, but one that also has a strong track record in the pharmaceutical sector.Oliver Dennis, CEO, Fishawack